Your browser doesn't support javascript.
loading
Risk and benefit of statins in stroke secondary prevention.
Laloux, Patrice.
Afiliación
  • Laloux P; Department of Neurology, CHU Mont-Godinne, Institute of Neurosciences, Avenue Therasse 1, B- 5530 Yvoir, Belgium. patrice.laloux@uclouvain.be.
Curr Vasc Pharmacol ; 11(6): 812-6, 2013 Nov.
Article en En | MEDLINE | ID: mdl-24484462
ABSTRACT
Statin is now recommended in secondary prevention after stroke or transient ischemic attacks to reduce the risk of a new stroke or major cardiovascular events. However, some issues about the extent of the benefit in some stroke patients and the risk of cerebral hemorrhage remain debated. This review shows that statins are significantly effective in decreasing the risk of further strokes despite an increase in the risk of brain hemorrhage. A significant benefit was observed in men and women, in aged patients and possibly to a greater extent in patients with carotid artery stenosis. Intensive statin therapy lowering the LDL-cholesterol beyond the cut-off value of 1.8 mmol/L (70 mg/dl) seems to be more effective than less intensive treatment and without an increased risk of side effects. Overall, statins are well tolerated. Further prospective studies should clarify whether the effect is of the same magnitude in small vessel disease and how to select the patients to reduce the risk of cerebral hemorrhage.
Asunto(s)
Buscar en Google
Bases de datos: MEDLINE Asunto principal: Inhibidores de Hidroximetilglutaril-CoA Reductasas / Accidente Cerebrovascular / Prevención Secundaria Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Curr Vasc Pharmacol Asunto de la revista: ANGIOLOGIA / FARMACOLOGIA Año: 2013 Tipo del documento: Article País de afiliación: Bélgica
Buscar en Google
Bases de datos: MEDLINE Asunto principal: Inhibidores de Hidroximetilglutaril-CoA Reductasas / Accidente Cerebrovascular / Prevención Secundaria Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Límite: Animals / Humans Idioma: En Revista: Curr Vasc Pharmacol Asunto de la revista: ANGIOLOGIA / FARMACOLOGIA Año: 2013 Tipo del documento: Article País de afiliación: Bélgica